Financials data is unavailable for this security.
View more
Year on year Mangalam Drugs and Organics Ltd had net income fall from a gain of 12.70m to a loss of 90.49m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 17.45% to 19.18%.
Gross margin | 38.76% |
---|---|
Net profit margin | 0.89% |
Operating margin | 3.90% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Mangalam Drugs and Organics Ltd did not generate a significant amount of cash. However, the company earned 121.68m from its operations for a Cash Flow Margin of 3.30%. In addition the company generated 57.00m cash from financing while 179.05m was spent on investing.
Cash flow per share | 11.51 |
---|---|
Price/Cash flow per share | 11.18 |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -812.51%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 128.11 |